{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:34:25Z","timestamp":1791470065393,"version":"4.3.4"},"reference-count":22,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2025,9,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      The CD4-binding site antibody VH3810109 (N6LS) demonstrated broad and potent neutralization activity\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      and robust antiviral activity in people with HIV-1. We report safety, tolerability, pharmacokinetics, and anti-drug antibody (ADA) incidence for subcutaneous (SC) and intravenous (IV) N6LS. Safety and pharmacokinetics of a single dose of VH3810109 (also known as GSK3810109), administered either subcutaneously (SC) with rHuPH20 or intravenously (IV) [SPAN]) was an open-label, three-part, phase 1 study evaluating single-dose N6LS in adults without HIV (part 1, 20 mg\/kg SC + recombinant human hyaluronidase PH20 [rHuPH20] 2,000 U\/mL; part 2, 60 mg\/kg IV; part 3, 3,000 mg SC + rHuPH20 2,000 U\/mL). Over 24 weeks, adverse events (AEs), injection site reactions (ISRs), pharmacokinetics, and ADAs were monitored. Twenty-four participants (8\/part) were enrolled and received a single N6LS dose. Overall AE incidence between SC doses was similar and higher compared with IV, driven by ISRs. No ISRs were reported for IV N6LS; for SC, 15\/16 participants reported ISRs, and 17\/32 events were grade 3 (all injection site erythema). All ISRs resolved without sequelae or treatment. All participants rated local reactions and pain as acceptable. No serious AEs or deaths occurred. Pharmacokinetics were as expected for a broadly neutralizing antibody; median terminal half-life ranged from 43 to 47 days. No ADAs were observed after IV N6LS (0\/8); 5\/16 participants had treatment-emergent ADAs after SC N6LS; however, a clear impact on pharmacokinetics was observed in only one participant. N6LS administered IV or SC + rHuPH20 had a favorable safety profile and was well tolerated. Results support the ongoing development of N6LS 3,000 mg SC + rHuPH20 and 60 mg\/kg IV into phase 2b.\n                    <\/jats:p>\n                    <jats:sec>\n                      <jats:title>CLINICAL TRIALS<\/jats:title>\n                      <jats:p>\n                        Registered at ClinicalTrials.gov (\n                        <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05291520\" xlink:type=\"simple\">NCT05291520<\/jats:ext-link>\n                        ).\n                      <\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1128\/aac.00258-25","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T12:00:50Z","timestamp":1753272050000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":2,"title":["VH3810109 (N6LS) broadly neutralizing antibody safety, pharmacokinetics, and anti-drug antibody incidence in adults without HIV: phase 1 SPAN study results"],"prefix":"10.1128","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6012-091X","authenticated-orcid":true,"given":"Peter A.","family":"Leone","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01cc9yk21","id-type":"ROR","asserted-by":"publisher"}],"name":"ViiV Healthcare","place":["Durham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Losos","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01cc9yk21","id-type":"ROR","asserted-by":"publisher"}],"name":"ViiV Healthcare","place":["Durham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wannamaker","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01cc9yk21","id-type":"ROR","asserted-by":"publisher"}],"name":"ViiV Healthcare","place":["Durham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"D\u2019Agostino","sequence":"additional","affiliation":[{"name":"GSK","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Warwick-Sanders","sequence":"additional","affiliation":[{"name":"GSK","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela L.","family":"Ghita","sequence":"additional","affiliation":[{"name":"GSK","place":["Collegeville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Wilches","sequence":"additional","affiliation":[{"name":"GSK","place":["Collegeville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Donatti","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01cc9yk21","id-type":"ROR","asserted-by":"publisher"}],"name":"ViiV Healthcare","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Brown","sequence":"additional","affiliation":[{"name":"Certara","place":["Radnor, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash","family":"Gandhi","sequence":"additional","affiliation":[{"name":"GSK","place":["Collegeville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa377"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04597-1"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature14411"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4268"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031738"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30053-0"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000600"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.10.027"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00498-17"},{"key":"e_1_3_3_11_2","volume-title":"Abstr 19th European AIDS Conference","author":"Edwards AY","year":"2023","unstructured":"Edwards AY, Ashraf W, Zweers T, Brown K, Losos J, Leone P, Gartland M, Wannamaker P, Lataillade M, Gandhi Y. 2023. Pharmacokinetics\/Pharmacodynamics and virological activity of VH3810109 (N6LS) in antiretroviral-naive viremic adults from the phase 2a BANNER study. Abstr 19th European AIDS Conference; abstr eP.A.099"},{"key":"e_1_3_3_12_2","volume-title":"Abstr 19th European AIDS Conference","author":"Leone P","year":"2023","unstructured":"Leone P, Cahn P, Rolle C-P, Klein M, Bettacchi C, Losos J, Griesel R, Warwick-Sanders M, Win B, Gandhi Y, D\u2019Agostino R, Wannamaker P, Abberbock J, Lataillade M. 2023. Safety and tolerability of VH3810109 (N6LS) among antiretroviral therapy\u2013naive adults living with HIV-1: results from the monotherapy phase of the phase 2a BANNER study. Abstr 19th European AIDS Conference; abstr PS8.O5"},{"key":"e_1_3_3_13_2","volume-title":"Abstr HIV Drug Therapy Glasgow","author":"Leone P","year":"2022","unstructured":"Leone P, Ferro A, Rolle C-P, Lupo S, McGowan J, Klein M, Cahn P, Benson P, Sanchez M, Bettacchi C, Schneider S, Wannamaker P, Win B, Abberbock J, Baker M, Wilches V, Bentley D, Gartland M, Lataillade M, Losos J. 2022. VH3810109 (N6LS) reduces viremia across a range of doses in ART-naive adults living with HIV: proof of concept achieved in the phase IIa BANNER (207959, NCT04871113) study. Abstr HIV Drug Therapy Glasgow; abstr O34"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01101-6"},{"key":"e_1_3_3_15_2","volume-title":"Hylenex recombinant [prescribing information]","author":"Halozyme, Inc","year":"2024","unstructured":"Halozyme, Inc. 2024. Hylenex recombinant [prescribing information]. Halozyme, Inc, San Diego, CA."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2021.1981286"},{"key":"e_1_3_3_17_2","volume-title":"Abstr 30th Conference on Retroviruses and Opportunistic Infections","author":"Wu RL","year":"2023","unstructured":"Wu RL, Houser KV, Happe M, Gaudinski MR, Awan SF, Widge AT, Holman LA, Saunders J, Buettner C, Lin BC, Castro M, Capparelli EV, Seder RA, Koup RA, Dropulic LK. 2023. N6LS with rHuPH20 enables safe high dose monoclonal antibody subcutaneous delivery. Abstr 30th Conference on Retroviruses and Opportunistic Infections; abstr 499"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-21"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12692"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3150"},{"key":"e_1_3_3_21_2","volume-title":"HyQvia [prescribing information]","author":"Takeda Pharmaceuticals USA, Inc","year":"2024","unstructured":"Takeda Pharmaceuticals USA, Inc. 2024. HyQvia [prescribing information]. Takeda Pharmaceuticals USA, Inc, Lexington, MA."},{"key":"e_1_3_3_22_2","volume-title":"Abstr 27th Conference on Retroviruses and Opportunistic Infections","author":"Widge AT","year":"2020","unstructured":"Widge AT, Houser KV, Gaudinski MR, Carter C, Hickman SP, Saunders J, Holman L, Gordon I, O\u2019Connell S, Capparelli EV, Connors M, Chen GL, Koup RA, Mascola JR. 2020. Phase I dose-escalation study of human monoclonal antibody N6LS in healthy adults. Abstr 27th Conference on Retroviruses and Opportunistic Infections; abstr 508"},{"key":"e_1_3_3_23_2","volume-title":"Immunogenicity assessment for therapeutic protein products: guidance for industry","author":"US Department of Health and Human Services","year":"2014","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. 2014. Immunogenicity assessment for therapeutic protein products: guidance for industry. Food and Drug Administration, Silver Spring, MD."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00258-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00258-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T13:02:05Z","timestamp":1756904525000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00258-25"}},"subtitle":[],"editor":[{"given":"Miguel Angel","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,3]]}},"alternative-id":["10.1128\/aac.00258-25"],"URL":"https:\/\/doi.org\/10.1128\/aac.00258-25","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"assertion":[{"value":"2025-02-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00258-25"}}